Market Overview

UPDATE: BMO Capital Markets Initiates Abbott Laboratories at Outperform on Growth, Margin Expansion

Share:
Related ABT
Benzinga's M&A Chatter for Monday February 1, 2015
Mid-Afternoon Market Update: Roper Technologies Falls Following Weak Results; Questar Shares Spike Higher

BMO Capital Markets initiated coverage on Abbott Laboratories (NYSE: ABT) with an Outperform rating and a $36 price target.

BMO Capital Markets noted, "The new Abbott is expected to deliver 2012E sales of $21.5B (flat; up 4% ex-FX) from four distinct businesses: Nutritionals (30% of sales); Medical Products (26%); Established Pharmaceuticals (24%); and Diagnostics (20%). With leading market share positions and an extensive geographic footprint, particularly in the emerging markets (about 40% of revenue), we expect the company to benefit from a focused management team and dedicated resources, to drive mid- to high-single-digit revenue growth, expand operating margins, and deliver double-digit EPS."

Abbott Laboratories closed at $31.40 on Monday.

Latest Ratings for ABT

DateFirmActionFromTo
Feb 2016Argus ResearchUpgradesHoldBuy
Jan 2016William BlairDowngradesOutperformMarket Perform
Jan 2016JefferiesMaintainsBuy

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

Posted-In: BMO Capital MarketsAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (ABT)

Get Benzinga's Newsletters